Indian Scientists Develop 'Smart' Cancer Drug RK-251 That Targets Tumour Cells
Published
Scientists in India have developed a new cancer drug that is designed to become active mainly inside cancer cells. The drug, called RK-251, is described as a "smart" drug because it aims to attack tumour cells while leaving healthy cells alone.
Many traditional cancer treatments, such as chemotherapy, affect both cancerous and healthy cells. This can cause side effects, including tiredness, hair loss and weakened immunity, because healthy cells in the body are also damaged. A drug that works mainly in tumour cells could, in principle, reduce this kind of harm to the rest of the body.
The idea behind RK-251 is to activate the drug primarily inside cancer cells. Targeted approaches like this are an important area of cancer research around the world, and they are becoming more common in the search for better treatments. The development of RK-251 shows that Indian researchers are taking part in this work.
The available information about RK-251 is still limited. Further details, such as testing results, clinical trial stages and when the drug might be available to patients, were not included in the report. Readers should wait for more information from official sources before drawing conclusions about how the drug will be used in medical treatment.
Sources: DD News
More India news
- Cheaper Batteries Make Solar and Wind the Lowest-Cost Power Source in India, Says BNEF
- Why Money Flowing Out of India Is Drawing Attention
- Qualcomm Layoffs: What Severance Will Former Employees in India Receive?
- Suriya's Cop Comedy 'Scene' Earns Rs 111 Crore in Five Days at the Box Office
- Ajay Devgn's Drishyam 3: The Conclusion Passes Rs 588 Crore Worldwide After 40 Days
- Ramayana: Part 1 Continues Strong Box Office Run with Rs 440 Crore Collection
- Government Uses Online Marketplace to Buy Farm and Allied Sector Goods
- World Bank Estimates Extreme Poverty in India at 2.6 Per Cent, Sparking Debate